Human papillomavirus and vaccination. Mayo Clin Proc 2008 Jun;83(6):701-706.
1st ed. Immunization, Vaccine and Biological World Health Organization; 2009.
Consensus recommendations on immunization. Indian Pediatr 2008 Aug;45(8):635-648.
Centers for disease control and prevention (CDC); Advisory committee onImmunization Practices (ACIP). Quadrivalent Human Pappilomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007 Mar 23;56(RR-2):1-24.
Indian HPV Vaccine Study Group. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women. J Obstet Gynaecol Res 2010 Feb;36(1):123-132.
Prevention strategies against the human papillomavirus: the effectiveness of vaccination. Gynecol Oncol 2007 Nov; 107(2 Suppl 1):S19-S23.
2003 (April). Swedish National Control study. (2006-2010).
Safety, efficacy and immunogenicity of quadrivalent HPV vaccine (Gardasil) in women aged 24-45. Presented at 24th International Papillomavirus Congress, November 3-9, 2007, Beijing [abstract PA1-04].
HPV vaccines. In: Plotkin SA, Orenstein WA, editors. Vaccines. 5th ed. Philadelphia: Saunders; 2008. p. 243-277.
Correlating immunity with protection for HPV infection. Int J Infect Dis 2007 Nov;11(Suppl 2):S10-S16.
Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009 Oct;5(10):705-719.
Human papilloma virus vaccines and current controversy. Indian Pediatr 2011 Mar;48(3):248-249.